埃隆·马斯克(Elon Musk)站台的司美格鲁肽痛失全球“药王”王冠。2月4日,诺和诺德发布2025年财报。数据显示,诺和诺德全年营收3090.64亿丹麦克朗(约合489亿美元),同比增长6%。其中,王牌单品司美格鲁肽贡献了361亿美元销售额,同比增长超过10%。但与其竞争对手美国礼来公司的替尔泊肽相比,司美格鲁肽还是少了约4亿美元。这也使得后者问鼎2025年新“药王”。与此同时,礼来还在财报中...
Source Link埃隆·马斯克(Elon Musk)站台的司美格鲁肽痛失全球“药王”王冠。2月4日,诺和诺德发布2025年财报。数据显示,诺和诺德全年营收3090.64亿丹麦克朗(约合489亿美元),同比增长6%。其中,王牌单品司美格鲁肽贡献了361亿美元销售额,同比增长超过10%。但与其竞争对手美国礼来公司的替尔泊肽相比,司美格鲁肽还是少了约4亿美元。这也使得后者问鼎2025年新“药王”。与此同时,礼来还在财报中...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.